Clinical Trials
13 trialsNCT00544115 2026-06-02
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03598998 2026-05-26
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT05944562 2026-05-20
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Washington University School of Medicine
Phase 1 Active not recruiting
NCT02978625 2026-05-13
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04652960 2026-05-13
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT02520791 2026-04-13
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04960618 2026-03-23
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT01352520 2026-01-20
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03278782 2026-01-09
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT03602157 2026-01-06
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT03011814 2025-09-18
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT03385226 2024-12-09
PORT
University College, London
Phase 2 Active not recruiting